看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。- Z% N" M% L2 N: u" ~% l9 i. R
6 W- ^# ]) Q- J/ W9 q4 @
2 T$ ^' l4 Q# C; s8 A, LCurrently available feasibility data for possible combination strategies. 0 _0 q6 ^' \) h' T
————————————————————————————————
. c, G' G( n# P# w9 XCombination Feasibility according to preliminary data - u8 j! _6 d/ l' N: c \$ x- u
——————————————————————————————————5 Z) p) v( t" @) K
Bevacizumab + sorafenib Yes, reduced dose ' T- v& q2 V5 @6 z( L+ K- O
Bevacizumab + sunitinib† No
: J4 ]' ]4 J, j$ f2 NBevacizumab + temsirolimus Yes 0 _0 p& \; G1 b+ s6 b8 G
Bevacizumab + everolimus Yes
. P# e0 W8 T) d1 i uSorafenib + sunitinib ?
: f$ D( r9 F( ~: _3 a' MSorafenib + temsirolimus Yes, reduced dose 0 e* m- v; ]& A1 Y
Sorafenib + everolimus Yes, reduced dose 1 V3 U; b k7 B9 o" j" `
Sunitinib + temsirolimus† No
& H# Y& n6 f, q) P8 u. JSunitinib + everolimus ?
7 ^: R1 F5 L' q, H* xTemsirolimus + everolimus ? 5 n' {, a: v9 `+ z* r. ?8 X' [
————————————————————& R( [, t* {. i( x# l
†Led to US FDA warning.
5 G' ~7 \; @, D0 S" S3 V) R?: As yet unattempted combination.
% F4 Z( i3 ~' p4 A9 k: @ |